BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Momelotinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Momelotinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04176198-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Momelotinib: Phase 1/2 readout est. (NCT04176198)
DESCRIPTION:Momelotinib\, phase 1/2.\nStudy: A Study of Oral Nuvisertib (TP
 -3654) in Patients With Myelofibrosis\nEstimated primary completion: 30 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/momelotinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041
 76198
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05980806-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Momelotinib: Phase 2 readout est. (NCT05980806)
DESCRIPTION:Momelotinib\, phase 2.\nStudy: A Study of Selinexor Monotherapy
  in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thromboc
 ytopenia\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05980806
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06150157-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Momelotinib: Phase 1 readout est. (NCT06150157)
DESCRIPTION:Momelotinib\, phase 1.\nStudy: A Study of JNJ-88549968 for the 
 Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms\nEst
 imated primary completion: 14 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06150157
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06847867-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Momelotinib: Phase 2 readout est. (NCT06847867)
DESCRIPTION:Momelotinib\, phase 2\, Myelodysplastic Syndromes.\nStudy: A St
 udy of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome\
 nEstimated primary completion: 14 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06847867
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06235801-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Momelotinib: Phase 1/2 readout est. (NCT06235801)
DESCRIPTION:Momelotinib\, phase 1/2.\nStudy: A Phase I/II Study of Gilterit
 inib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated
  Acute Myeloid Leukemia\nEstimated primary completion: 1 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/momelotinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06235801
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071155-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20280305
DTEND;VALUE=DATE:20280306
SUMMARY:Momelotinib: Phase 1 readout est. (NCT07071155)
DESCRIPTION:Momelotinib\, phase 1\, Myelodysplastic Syndromes.\nStudy: Mome
 lotinib in Combination With Hypomethylating Agent for Chronic Phase Myelod
 ysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutr
 ophilic Leukemia\nEstimated primary completion: 5 March 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/momelotinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07071155
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098936-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Momelotinib: Phase 2 readout est. (NCT07098936)
DESCRIPTION:Momelotinib\, phase 2.\nStudy: Momelotinib in VEXAS Syndrome\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07098936
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07734077-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Momelotinib: Phase 1/2 readout est. (NCT07734077)
DESCRIPTION:Momelotinib\, phase 1/2.\nStudy: Revumenib in Patients With Mye
 lofibrosis\nEstimated primary completion: 1 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/momelotinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07734077
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498205-3097@assetmemo.bio
DTSTAMP:20261121T010443Z
DTSTART;VALUE=DATE:20290808
DTEND;VALUE=DATE:20290809
SUMMARY:Momelotinib: Phase 4 readout est. (NCT07498205)
DESCRIPTION:Momelotinib\, phase 4.\nStudy: Comparing Momelotinib and Ruxoli
 tinib in People With Untreated Myelofibrosis and Low Blood Cell Counts\nEs
 timated primary completion: 8 August 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/momelotinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07498205
URL:https://assetmemo.bio/drug/momelotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
